Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma
Y. Zheng (South San Francisco, United States of America), Y. Guan (South San Francisco, United States of America), Y. Gao (Shanghai, China), L. Liu (Shanghai, China), L. Abuqayyas (Cambridge, United States of America), Å. Hellqvist (Gothenburg, Sweden), K. Bowen (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America), A. Macdonald (Cambridge, United Kingdom)
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Session: Asthma clinical trials and real-life studies
Session type: E-poster
Number: 884
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Zheng (South San Francisco, United States of America), Y. Guan (South San Francisco, United States of America), Y. Gao (Shanghai, China), L. Liu (Shanghai, China), L. Abuqayyas (Cambridge, United States of America), Å. Hellqvist (Gothenburg, Sweden), K. Bowen (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America), A. Macdonald (Cambridge, United Kingdom). Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma. 884
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: